Sign in

CPMD on OTC

CANNAPHARMARX, INC.

CANNAPHARMARX, INC. is an American pharmaceutical preparations company, incorporated in Delaware.1 Its shares trade on OTC under the symbol CPMD.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with BeyondSpring Inc., Northwest Biotherapeutics or AVENUE THERAPEUTICS, INC., or pick any stock.

  • TickerCPMD on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersDE1
  • Incorporated inDE2
  • Business address4439 Township Rd 304, Mountain View County, T0M 0R02
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-153.1%Gross margin4
-245.8%Operating margin4
-817.2%Net margin4
66.1%Revenue growth, 20254
-$794.6KFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue64¢$3.4M
  • Interest36¢$2.0M

Out of $1.4M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$1.4M in 2025
0$500.0K$1.0M$1.5M2019: $0$020192020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $820.1K$820.1K20242025: $1.4M$1.4M2025+66%
Gross profit84-$2.1M in 2025
-$3.0M-$2.0M-$1.0M02023: $0$020232024: -$2.9M-$2.9M20242025: -$2.1M-$2.1M2025−29%
Operating income56784-$3.3M in 2025−79% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$16.0M-$16.0M20192020: -$14.5M-$14.5M2020−9%2021: -$3.0M-$3.0M2021−79%2022: -$5.2M-$5.2M2022+74%2023: -$1.6M-$1.6M2023−70%2024: -$3.6M-$3.6M2024+130%2025: -$3.3M-$3.3M2025−8%
Net income56784-$11.1M in 2025−46% since 2019
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$20.5M-$20.5M20192020: -$19.9M-$19.9M2020−3%2021: -$8.8M-$8.8M2021−56%2022: -$8.5M-$8.5M2022−3%2023: $3.7M$3.7M20232024: -$9.9M-$9.9M20242025: -$11.1M-$11.1M2025+12%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$1.4M$820.1K
Cost of goods sold$3.4M$3.8M
Gross loss-$2.1M-$2.9M
General and administrative$489.6K$145.7K
Payroll and consulting fees$0$114.8K
Professional fees$469.7K$435.5K
Royalty expense$303.5K$0
Total operating expenses$1.3M$696.0K
Loss from operations-$3.3M-$3.6M
Change in the fair value of derivative conversion feature-$850.2K$105.1K
Change in the fair value of obligation to issue shares$1.5M-$3.4M
Foreign exchange gain$66.3K$24.7K
Interest expense-$2.0M-$2.3M
Imputed interest expense-$490.6K$0
Loss on the extinguishment of debt$0-$690.7K
Loss on impairment of investment-$4.5M$0
Gain on write-off of accounts payable and accrued liabilities$410.4K$0
Other expense-$1.9M$0
Total other expenses-$7.8M-$6.3M
Net loss-$11.1M-$9.9M
Foreign currency translation adjustment-$612.3K$591.2K
Net comprehensive loss-$11.7M-$9.3M
Basic and diluted loss per share of common shares-$0.02-$0.02
Weighted average number of shares outstanding662.5M shares625.3M shares

Compare CANNAPHARMARX, INC. with another company

What it owns

What CANNAPHARMARX, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$210.9K8 Dec 31, 2024$209.4K8 Dec 31, 2023+0.7%
Accumulated depreciation$73.6K8 Dec 31, 2024$47.9K8 Dec 31, 2023+53.7%
Property and equipment, net$127.0K4 Dec 31, 2025$137.2K4 Dec 31, 2024−7.4%
Operating-lease assets (leased space)$5.6M4 Dec 31, 2025$5.2M4 Dec 31, 2024+8.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.8K4 Dec 31, 2025$2.2K4 Dec 31, 2024−16.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.1M4 Dec 31, 2025$996.2K4 Dec 31, 2024+12.0%
Work in process$774.3K4 Dec 31, 2025$1.6M4 Dec 31, 2024−50.4%
Finished goods$827.5K4 Dec 31, 2025$752.1K4 Dec 31, 2024+10.0%

Properties, in its own words

Our executive offices are located at 4439 Township Road 304, Mountain View County, Alberta, Canada T0M 0R0. Our growing facility which is located in Cremona, Alberta is subject to a 20-year operating lease with Formosa Mountain, which became a related party upon the appointment of its manager, Elliot Zemel, as a director of the Company on March 11, 2025 and will expire in 2042. We utilize this 55,000 square foot facility for growing, drying and packaging of our cannabis products. Lease payments for the growing facility are subject to annual increases. Our rent for the Facility in 2025 was $125,000 CAD per month. We believe that our facilities are sufficient for our current business purposes.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led CANNAPHARMARX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David J. Cutler2007
  2. Gerald Eugene Crocker Jr.2014–2015
  3. Dominic Colvin2019–2020

Chief financial officer

  1. David J. Cutler2007
  2. Gary J. Herick2014–2019
  3. Christopher P. Schnittker2015
  4. John Hamilton Cassels2020

Chief operating officer

  1. Andrew Clifford Steedman2020
2010201520202025
Board members and other officers (19)

Former names

  • CCVG, INC.Jan 12, 2011 to Jan 12, 20112
  • GOLDEN DRAGON HOLDING CO.Dec 30, 2010 to Oct 27, 20142
  • CONCORD VENTURES, INC.Oct 30, 2007 to Nov 17, 20102
  • CAVION TECHNOLOGIES INCJul 29, 1999 to Jul 25, 20072

Timeline

  1. Jan 13, 20268-K Executive or director change; Other events35
  2. Dec 18, 20258-K Other events36
  3. Oct 10, 20258-K Other events37
  4. May 6, 20258-K Other events38
  5. Mar 31, 20258-K Executive or director change39
  6. Dec 3, 20248-K Change of auditor40
  7. Nov 21, 20248-K Change of auditor41
  8. Sep 17, 20248-K Executive or director change42
  9. Feb 22, 20248-K Financial statements and exhibits43
  10. Feb 16, 20248-K Entered a material agreement44
  11. Dec 6, 20238-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares45
  12. Nov 13, 20238-K Change of auditor46
  13. Jun 26, 2019New chief executive Dominic Colvin becomes CEO13
  14. Sep 12, 2014New chief executive Gerald Eugene Crocker Jr. becomes CEO14
  15. Oct 30, 2007New chief executive David J. Cutler becomes CEO15

Filings

63 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 16 major events, 3 insider forms, 24 other. The latest 20:

  1. Aug 18, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
  2. Aug 17, 2026NT 10-Q EDGAR
  3. May 20, 202610-Q EDGAR
  4. May 18, 2026NT 10-Q EDGAR
  5. Mar 31, 202610-K EDGAR
  6. Jan 13, 20268-K EDGAR
  7. Dec 18, 20258-K EDGAR
  8. Nov 14, 202510-Q EDGAR
  9. Oct 10, 20258-K EDGAR
  10. Aug 22, 2025144 EDGAR
  11. Aug 14, 202510-Q EDGAR
  12. May 22, 2025144 EDGAR
  13. May 16, 202510-Q EDGAR
  14. May 16, 2025NT 10-Q EDGAR
  15. May 6, 20258-K EDGAR
  16. Apr 10, 202510-K EDGAR
  17. Apr 10, 20253 EDGAR
  18. Apr 10, 20253 EDGAR
  19. Apr 1, 2025NT 10-K EDGAR
  20. Mar 31, 20258-K EDGAR

The 63 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How CANNAPHARMARX, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCANNAPHARMARX, INC.1
  • CIK0001081938
  • Employer ID (EIN)27-46351403
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4439 Township Rd 304, Mountain View County, Alberta T0M 0R0, Alberta, Canada1
  • Phone949-652-68381
  • Shares outstanding708,689,905 as of Aug 18, 202611
  • Public float$2.6M as of Jun 30, 20253
  • AuditorBARZILY AND CO., CPA’s, Jerusalem, Israel PCAOB ID 20153
  • On EDGAR sinceJun 10, 19991
  • Filings365 in all: 8-K (74), 10-Q (56), 3 (27), 10-K (18), 4 (18), NT 10-Q (16), CORRESP (13), UPLOAD (13)1
    All 45 form types

    NT 10-K (10), DEF 14A (8), SC 13D (8), 424B3 (7), 8-K/A (7), SB-2/A (7), 10-K/A (6), D (6), 10QSB (5), S-1/A (5), SC 13G (5), SC 13G/A (5), 10-Q/A (4), EFFECT (4), PRE 14A (4), S-1 (4), D/A (3), POS AM (3), SB-2 (3), SC 13D/A (3), 144 (2), 3/A (2), 4/A (2), DEFS14A (2), PRES14A (2), S-8 (2), 10KSB (1), 10KSB40 (1), 10SB12G (1), 15-12G (1), 8-A12G (1), DEF 14C (1), DEFA14A (1), DEL AM (1), PRE 14C (1), RW (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 18, 2026
    Proxy statement (DEF 14A) Oct 4, 2022
    Latest 8-K (8-K) Jan 13, 2026

Securities registered for trading

ClassSymbolExchange
CPMD

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks CANNAPHARMARX, INC. names in Item 1A of its 10-K filed Mar 31, 2026: 40 risks under these headings, as written.3

  • Substantial doubt about the Company’s ability to continue as a going concern.
  • We have a history of losses and will require financing, which may not be available.
  • We have had a limited operating history in the cannabis industry and our ability to grow sales and achieve profitability is questionable.
  • We will need to raise additional funds in the future that may not be available on acceptable terms or available at all.
  • Convertible notes in default and related penalty provisions may adversely affect our financial condition
  • Our actual financial position and results of operations may differ materially from management’s expectations.
  • The Company is reliant on the retention of licenses to produce medical and recreational cannabis products in Canada.
  • We are subject to changes in Canadian laws, regulations and guidelines which could adversely affect our future business, financial condition and results of operations.
  • We may not be able to develop our products which could prevent us from ever becoming profitable.
  • No assurance of sustainable revenues.
  • We may not be able to effectively manage our growth and operations, which could materially and adversely affect our business.
  • We face competition from companies that have significantly greater resources.
The other 28 risks
  • If we are unable to attract and retain key personnel, we may not be able to compete effectively in the cannabis market.
  • If we are unable to keep up with technological developments, our business could be negatively affected.
  • We may be exposed to significant currency exchange fluctuations.
  • We may be subject to product recalls self-imposed or imposed by regulators for product defects.
  • Changes in product specifications and regulatory standards could have a material adverse effect on our costs and operating results.
  • We are reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on our finances and operating results.
  • We may be subject to liability claims for damages and other expenses not covered by insurance.
  • We operate within the cannabis industry, which might result in additional difficulties and complexities associated with obtaining adequate insurance coverage.
  • The cultivation of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others.
  • The cultivation of cannabis involves a reliance on third party distribution services which could result in supply delays, reliability of delivery and other related risks.
  • We are reliant on information technology systems and may be damaged by cyber attacks.
  • We may be subject to breaches of security at our Canadian facility, or in respect of electronic documents and data storage and may face risks related to breaches of applicable privacy laws.
  • We may in the future be subject to legal proceedings, regulatory disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management’s attention, and materially harm our business, results of operations, cash flows, and financial condition.
  • Risks Related to the Regulatory System and Business Environment for Cannabis
  • The expansion of the medical and recreational cannabis industry may require new clinical research into effective medical therapies.
  • Regulatory restrictions on the marketing and sale of cannabis products in our target markets could materially impact our operating results.
  • Publicity or consumer perception may influence our business.
  • Regulatory scrutiny of our industry may negatively impact our ability to raise additional capital.
  • A limited public trading market exists for our common shares, which makes it difficult for our shareholders to sell their common shares. Any trading in our shares may have a significant effect on our share price.
  • We may be subject to heightened scrutiny by United States and Canadian authorities, which could ultimately lead to the market for our common shares becoming highly illiquid and our shareholders having no ability to effect trades
  • Existing shareholders may be diluted to the extent we raise additional funds through future equity financings
  • Our share price has undergone a great deal of volatility, including a significant decrease over the past few years.
  • Our common shares are categorized as penny shares. Trading of our shares are restricted by the SEC’s penny shares regulations which may limit a shareholder’s ability to buy and sell our shares
  • Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit a shareholder’s ability to buy and sell our shares
  • We have not voluntarily implemented various corporate governance measures, in the absence of which, shareholders may have more limited protections against interested director transactions, conflicts of interest and similar matters
  • To date, we have not paid any cash dividends, and no cash dividends will be paid in the foreseeable future
  • If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately to report our financial results or prevent financial fraud. As a result, current and potential shareholders could lose confidence in our financial reporting
  • Because our current directors, executive officers, and preferred shareholders beneficially own or control 30.7% of our common shares on a fully diluted basis, they can exert significant control over our business and affairs and have actual or potential interests that may depart from those of our other shareholders.
  • Our articles of incorporation allow our board to create new series of preferred shares without approval by our shareholders, which could adversely affect the rights of the holders of our common shares

Legal proceedings

Steven Barber

As part of our acquisition of Alternative Medical Solutions Inc. (“AMS”) in 2018, we are currently reviewing with our legal counsel to ascertain whether we have claims against Steven Barber arising out of his default of the Consulting Agreement we entered into as part of the AMS acquisition. In January 2020, we received correspondence from counsel for Mr. Barber demanding payment on amounts purported to be due pursuant to his Consulting Agreement with us. We have reviewed whether Mr. Barber has performed pursuant to the terms of the Consulting Agreement and noticed concerns.

No decision on whether to proceed on either of these situations has been reached as at the date of this report, but we do not believe that these situations present a probability of material risk and therefore a loss contingency is not reflected in our consolidated financial statements. As of December 31, 2025, we have an outstanding payable of $549,780 (December 31, 2024 - $549,780).

Deloitte LLP

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
    SEC EDGAROther events
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46